Biocryst Pharmaceuticals (BCRX) Leases (2023 - 2025)
Biocryst Pharmaceuticals' Leases history spans 3 years, with the latest figure at $7.5 million for Q4 2025.
- For Q4 2025, Leases rose 91.23% year-over-year to $7.5 million; the TTM value through Dec 2025 reached $7.5 million, up 91.23%, while the annual FY2025 figure was $7.5 million, 91.23% up from the prior year.
- Leases reached $7.5 million in Q4 2025 per BCRX's latest filing, down from $7.7 million in the prior quarter.
- In the past five years, Leases ranged from a high of $11.4 million in Q3 2023 to a low of $3.9 million in Q4 2024.
- Average Leases over 3 years is $7.9 million, with a median of $7.9 million recorded in 2025.
- Peak YoY movement for Leases: crashed 54.54% in 2024, then surged 91.23% in 2025.
- A 3-year view of Leases shows it stood at $8.7 million in 2023, then plummeted by 54.54% to $3.9 million in 2024, then soared by 91.23% to $7.5 million in 2025.
- Per Business Quant, the three most recent readings for BCRX's Leases are $7.5 million (Q4 2025), $7.7 million (Q3 2025), and $7.9 million (Q2 2025).